On April 30, 2024 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, reported its participation in the Sidoti Micro-Cap Virtual Conference, taking place May 8-9, 2024 (Press release, Anixa Biosciences, APR 30, 2024, View Source [SID1234642457]). Anixa Chairman and CEO Dr. Amit Kumar will present an overview of the Company and its clinical programs including vaccines to prevent cancer and a CAR-T cell therapy to treat cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Conference details:
Presentation: Thursday, May 9, 2024, at 11:30 am ET*
Presentation link: Click here to register; available via Zoom
Conference registration: Available on the conference website
1×1 meetings: Open to all investors upon conference registration
Dr. Kumar will discuss Anixa’s preventative breast cancer vaccine, currently in Phase 1 clinical trials, that is showing strong positive data. Additional data releases expected in the coming months, and a Phase 2 trial is expected to commence in early 2025. Anixa’s CAR-T cell therapy treatment for ovarian cancer is also in a Phase 1 trial and showing positive data. Anixa has a capital efficient business model, with greater than two years cash, no debt, and a clean cap table.
*The presentation date and time are subject to change. Participants should refer to the final program agenda for up-to-date information.